Radiation Oncology

Colleen A. Lawton, MD, FACR, FASTRO Professor of Radiation Oncology Director of Residency Program Department of Radiation Oncology 8701 Watertown Plank Road Milwaukee, WI 53226 (414) 805-4470

Curriculum Vitae

Patient Care Emphases

• Genital-Urinary Cancers
• Prostate Cancer
• Prostate Radioactive Seed Implantation
• Male Genital Cancer
• Total Body Irradiation for Bone Marrow Transplant

Clinical Practice Locations

• Froedtert & Medical College Clinical Cancer Center: (414) 805-4400
• Community Memorial Hospital: (262) 257-5151

Education

• Doctor of Medicine, Medical College of Wisconsin, Milwaukee, WI (1983).

Training

• Recertification, Radiation Oncology, American Board of Radiology (2000).
• Board Certification, Radiation Oncology, American Board of Radiology (1987).
• Residency Radiation Oncology, Medical College of Wisconsin Affiliated Hospitals, Milwaukee, WI (1984-1987).
• Internship Radiation Oncology, Medical College of Wisconsin, Milwaukee, WI (1983-1984).

Representative Publications (last 5 years)

• Lawton C, Michalski J, El-Naqa I, Buyyounouski M, Lee WR, Menard C, O’Meara E, Rosenthal S, Ritter M, Seider M.  RTOG GU Radiation Oncology Specialists Reach Consensus on Pelvic Lymph Node Volumes for High-Risk Prostate Cancer. Int J Rad Onc Bio & Phys 74(2):383-387, 2009.
• Lawton C, Michalski J, El-Naqa I, Kuban D, Lee WR, Rosenthal S, Zietman A, Sandler H, Shipley W, Ritter M, Valicenti R, Catton C, Roach M III, Pisansky T, Seider M.  Variation in the Definition of Clinical Target Volumes for Pelvic Nodal Conformal Radiation Therapy for Prostate Cancer. Int J Rad Onc Bio & Phys 74(2):377-382, 2009.  
• Wang D, Lawton C.  Pelvic Lymph Node Irradiation for Prostate Cancer - Who? Why? When? Seminars in Radiation Oncology, 18(1) 35-40, 2008.
• Lawton CA, Bae K, Pilepich M, Hanks G, Shipley W.  Long Term Treatment Sequelae Following External Beam Irradiation + Hormonal Manipulation for Adenocarcinoma of the Prostate: Analysis of RTOG Studies 85-31, 86-10, and 92-02. Int J Rad Onc Biol & Phys 70:2, 437-441, 2008.
• Roach M III, Bae K, Speight J, Wolkov H,  Rubin P , Lee RJ, Lawton C, Valicenti R, Grignon D,  Pilepich M.  Short Term Neoadjuvant Androgen Deprivation Therapy and External Beam Radiotherapy for Locally Advanced Prostate Cancer: Long Term Results of RTOG 8610 a Phase III Prospective Randomized Trial. Journal of Clinical Oncology 26:4, 585-591, 2008.
• Horwitz E, Bae K, Hanks G, Porter A, Grignon D, Brereton H, Venkatesan, V, Lawton C, Rosenthal S, Sandler H, Shipley W.  Ten-year follow-up of RTOG 92-02: A phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer. J Clin Onc 26:15; 2497-2504, May 2008.
• Li XA, Wang Z, Stewart RD, Dibiase DJ, Wang D, Lawton C.  Designing equivalent treatment regimens for prostate radiotherapy based on equivalent uniform dose. The British Journal of Radiology 81, 59-68, 2008.
• Ahunbay E, Peng C, Chen GP, Narayanan S, Yu C, Lawton C, Li XA.  An online real-time adaptive strategy to correct for inter-fractional variations. Med Phys 35, 3607, 2008.
• Lawton C, DeSilvio M,  Lee WR, Gomella L, Grignon D, Gillin M, Morton G, Pisansky T, Sandler H.  Results of a phase II trial of transrectal ultrasound guided permanent radioactive implantation of the prostate for definitive management of localized adenocarcinoma of the prostate. (RTOG 98-05) Int J Rad Onc Biol & Phys 67(1):39-47, 2007.
• Lawton C, DeSilvio M, Roach M III, Uhl V,  Kirsch R, Seider M, Rotman M, Jones C, Asbell S, Valicenti R, Hahn S,  Thomas Jr C.  An Update of the Phase III Trial Comparing Whole-Pelvic (WP) to Prostate Only (PO) Radiotherapy and Neoadjuvant to Adjuvant Total Androgen Suppression (TAS): Updated Analysis of RTOG 94-13, with Emphasis on Unexpected Hormone/Radiation Interactions. Int J Rad Onc Bio & Phs 69(3):646-655, 2007.
• Lee WR. Bae K. Lawton C. Gillin M. Morton G. Firat S. Baikadi M. Kuettel M. Greven K. Sandler H. Late toxicity and biochemical recurrence after external-beam radiotherapy combined with permanent-source prostate brachytherapy: analysis of Radiation Therapy Oncology Group study 0019. Cancer. 109(8):1506-12, 2007.
• Lee WR, DeSilvio M, Lawton C, Gillin M, Morton G, Firat S, Baikadi M, Kuettel M, Greven K, Sandler H.  A Phase II Study of External Beam Radiation Therapy Combined with Permanent Source Brachytherapy for Intermediate Risk Clinically Localized Adenocarcinoma of the Prostate: Preliminary Results of RTOG P-0019. Int J Rad Onc Bio & Phys 64:3, 804-809, 2006.
• Roach M III. DeSilvio M. Valicenti R. Grignon D. Asbell SO. Lawton C. Thomas CR Jr. Shipley WU.  Whole-pelvis, "mini-pelvis," or prostate-only external beam radiotherapy after neoadjuvant and concurrent hormonal therapy in patients treated in the Radiation Therapy Oncology Group 9413 trial. Int J of Rad Onc Bio Phy. 66(3):647-53, 2006.
• Gillin MT. Dunning BF. Lawton CA. Foley WD. Byhardt RW. Morton G. Baikadi M. Pisansky TT. Michalski JM. Ibbott G. Lopez F. Radiation Therapy Oncology Group. Quality assurance methods for the first Radiation Therapy Oncology Group permanent prostate implant protocol.[Clinical Trial, Phase II.] Brachytherapy 5(3):152-6, 2006.
• Shipley WU, DeSilvio M, Pilepich M, Roach M III, Mesic JB, Sause WT, Rubin P, Lawton C.  Early initiation of salvage hormone therapy influences survival in patients who failed initial radiation for locally advanced prostate cancer: A secondary analysis of RTOG protocol 86-10. Int J Rad Onc Biol Phys 64:4, pp 1162-1167, 2006.
• Lee WR. Bae K. Lawton CA. Gillin MT. Morton G. Firat S. Baikadi M. Kuettel M. Greven K. Sandler H: A descriptive analysis of postimplant dosimetric parameters from Radiation Therapy Oncology Group P0019. Brachytherapy 5(4):239-43, 2006.
• Lawton C, Winter K, Grignon D, and Pilepich M.  Androgen Suppression plus Radiation versus Radiation Alone for Patients with D1 (pN+) Adenocarcinoma of the Prostate Updated Results Based on a National Prospective Randomized Trial, RTOG 85-31). J Clin Oncol 23:4, 800-807, 2005.
• Pilepich M, Winter K, Lawton C, Krisch R, Wolkov H, Movsas B, Hug E, Asbell S, Grignon D.  Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma long term results of phase III RTOG 85-31. Int J Rad Onc Biol Phys, 61:5, 1285-1290, 2005.
• Feigenberg S, Lee WR, Desilvio M, Winter K, Pisansky T, Watkins-Bruner D, Lawton C, Morton G, Baikadi M, Sandler H.  Health-related quality of life in men receiving prostate brachytherapy on RTOG 98-05. Int J Rad Onc Biol Phys 62(4):956-64, 2005.
• Li XA, Wang JZ, Jursinic P, Lawton C, Wang D.  Dosimetric advantages of IMRT simultaneous integrated boost for high risk prostate cancer. Int J Rad Onc Biol Phys 61:4, 1251-1257, 2005.